Actelion Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACTELION, and when can generic versions of ACTELION drugs launch?
ACTELION has eight approved drugs.
There are fifteen US patents protecting ACTELION drugs.
There are two hundred and forty-five patent family members on ACTELION drugs in thirty-nine countries and thirty-four supplementary protection certificates in seventeen countries.
Summary for Actelion
International Patents: | 245 |
US Patents: | 15 |
Tradenames: | 6 |
Ingredients: | 6 |
NDAs: | 8 |
PTAB Cases with Actelion as petitioner: | See PTAB cases with Actelion as petitioner |
Drugs and US Patents for Actelion
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actelion | VELETRI | epoprostenol sodium | INJECTABLE;INJECTION | 022260-002 | Jun 28, 2012 | AP2 | RX | Yes | Yes | 8,598,227 | See Plans and Pricing | See Plans and Pricing | |||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-002 | Dec 21, 2015 | RX | Yes | Yes | 10,821,108 | See Plans and Pricing | Y | See Plans and Pricing | |||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-008 | Dec 21, 2015 | RX | Yes | No | 10,821,108 | See Plans and Pricing | Y | See Plans and Pricing | |||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-003 | Dec 21, 2015 | RX | Yes | No | 10,821,108 | See Plans and Pricing | Y | See Plans and Pricing | |||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-007 | Dec 21, 2015 | RX | Yes | No | 10,821,108 | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Actelion
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-002 | Nov 20, 2001 | 5,292,740 | See Plans and Pricing |
Actelion | ZAVESCA | miglustat | CAPSULE;ORAL | 021348-001 | Jul 31, 2003 | 5,472,969 | See Plans and Pricing |
Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-001 | Nov 20, 2001 | 5,292,740 | See Plans and Pricing |
Actelion | ZAVESCA | miglustat | CAPSULE;ORAL | 021348-001 | Jul 31, 2003 | 5,525,616 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACTELION drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Oral Suspension | 32 mg | ➤ Subscribe | 2019-02-08 |
➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2017-10-18 |
International Patents for Actelion Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | WO2010150865 | See Plans and Pricing |
South Korea | 101473022 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 02088084 | See Plans and Pricing |
Norway | 341325 | See Plans and Pricing |
Lithuania | 2447254 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Actelion Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1345920 | 92381 | Luxembourg | See Plans and Pricing | PRODUCT NAME: MACITENTAN ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(OPSUMIT) |
2447254 | PA2018008,C2447254 | Lithuania | See Plans and Pricing | PRODUCT NAME: SELEKSIPAGAS; REGISTRATION NO/DATE: EU/1/15/1083 20160512 |
1345920 | 2014C/019 | Belgium | See Plans and Pricing | PRODUCT NAME: MACITENTAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/13/893 20131227 |
1345920 | 300672 | Netherlands | See Plans and Pricing | PRODUCT NAME: MACITENTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/893/001-003 20131220 |
1345920 | 1490025-2 | Sweden | See Plans and Pricing | PRODUCT NAME: MACITENTAN; REG. NO/DATE: EU/1/13/893 20131220 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.